A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder

Psilocybin may serve as a novel therapy for major depression, with a clinical study planned to assess its safety and efficacy.

• Psilocybin is derived from mushrooms endemic to Mexico and shows potential as a treatment for major depression.
• The study includes a preclinical evaluation of toxicity and pharmacological effects using mice.
• A clinical trial will assess the safety and efficacy of psilocybin compared to traditional care in patients with major depressive disorder.
• Safety evaluations will focus on tolerated doses and pharmacokinetic parameters after oral administration in healthy adults.
• The research design involves fully characterizing the mushroom extract before clinical application.

AI simplified